Navigation Links
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Date:12/7/2007

nd safety of the addition of CDX-110 vaccine to standard of care, versus standard of care alone. Celldex has currently enlisted 18 clinical centers throughout the United States, and also recently received approval from Health Canada to open enrollment in Canada. Furthermore, The National Cancer Institute (NCI) has agreed to collaborate with Celldex in expanded clinical development of CDX-110 under a Clinical Trials Agreement.

"Obtaining orphan designation for CDX-110 is an important milestone for Celldex," said Thomas Davis, M.D., Chief Medical Officer of Celldex Therapeutics. "Approval to expand clinical research into Canada and the scientific and clinical collaboration from the National Cancer Institute all promote our ability to fully explore the promise of CDX-110."

About CDX-110

CDX-110 is an investigational immunotherapy that targets the tumor specific molecule EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), which is a protein that has been well validated as a target for cancer therapy. This particular variant, EGFRvIII occurs in about 40 percent of Glioblastoma Multiforme (GBM) patients. It was discovered in a collaborative effort between Dr. Bert Vogelstein and Dr Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Unlike EGFR, EGFRvIII is not present in normal tissues, suggesting this target will enable the development of a tumor-specific therapy for cancer patients. Furthermore, EGFRvIII is a transforming oncogene that can directly contribute to cancer cell growth. While originally discovered in GBM, the most common and aggressive form of brain cancer, the expression of EGFRvIII has also been observed in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head & neck cancers. Celldex has exclusive rights to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM therapy, as well as in other cancers through additional clinical studi
'/>"/>

SOURCE Celldex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... October 12, 2011 Aircraft Medical ("Aircraft"), ... has signed an exclusive agreement with Covidien (NYSE: ... products with 2010 revenue of $10.4 billion, and 41,000 ... agreement, Covidien will market and distribute Aircraft,s proprietary McGRATH ...
... October 12, 2011 OctreoPharm Sciences ... today that the European Medicines Agency has granted ... for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours. ... to ten year market exclusivity in Europe following ...
Cached Medicine Technology:Aircraft Medical Signs Multinational Distribution Agreement with Covidien for McGRATH® MAC Video Laryngoscope 2OctreoPharm Sciences Receives Orphan Drug Designation for SOMscan® for the Diagnosis of Neuroendocrine Tumours 2
(Date:4/24/2014)... has been awarded one of 30 grants from the ... Academic Participating Site in its new National Clinical ... select groups of investigators charged with distributing resources in ... NCTN grant system reflects recommendations from a 2010 ... achieve four goals:, Faster design, launch, and ...
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... Using frozen stool from healthy, unrelated donors was ... relapsing diarrhea caused by Clostridium difficile , ... Clinical Infectious Diseases and available online. ... equally effective whether given via a colonoscope or ... may make this promising treatment more readily available ...
(Date:4/23/2014)... Spokane have developed a new way to detect ... the wheel. , Their recently patented technology is ... in drowsy driversand offers an affordable and more ... detection systems. , Van Dongen"Video-based systems that use ... out of its lane are cumbersome and expensive," ...
(Date:4/23/2014)... April 23, 2014 The American Society for Radiation ... Role of Postoperative Radiation Therapy for Endometrial Cancer: ... of adjuvant radiation therapy in the treatment of ... in the May-June 2014 issue of Practical ... journal of ASTRO. The full-length guideline is available ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... , , , , ... Inc. announced today that the Dakim(R) BrainFitness(TM) System has now been adopted ... their defenses against dementia and memory loss. Dakim has added 136 new ... brain training system provider in the senior care market. , ...
... University of the Negev (BGU) researchers, in a collaboration ... identified a signaling pathway that is operational in intra-abdominal ... to obesity-related morbidity. The paper was just ... Clinical Endocrinology and Metabolism ( J. Clin. Endocrinol. ...
... ... Consumer Use , ... (Vocus) July 14, 2009 -- HemCon Medical Technologies , Inc. today announced that its ... and home settings for anterior nasal bleeding. The nasal care products will be available ...
... , DETROIT, July 14 Major depression ... billion. It is currently the leading cause of disability in the ... Approximately 4% of adolescents develop major depression each year and by 2020, ... , , All of this need ...
... any damage is to stop them in their tracks before ... Yiping Han, associate professor at the Case Western Reserve University ... roadblocks for a common bacterium that,s harmless in a mother,s ... child. She has received a five-year, $1.85 million grant ...
... (API), who are in the sexual minority, face psychological ... and ancestral cultures that significantly impact the development of ... teens and young adults identified as gay, lesbian, bisexual, ... their western or Caucasian peers, which can lead to ...
Cached Medicine News:Health News:Dakim BrainFitness Now Used in 286 Senior Living Communities, Adding 136 Sites in 12 Months for Dementia-Fighting System 2Health News:Dakim BrainFitness Now Used in 286 Senior Living Communities, Adding 136 Sites in 12 Months for Dementia-Fighting System 3Health News:Ben-Gurion U. researchers identify how stressed fat tissue malfunctions 2Health News:New HemCon/Seal-On Nasal Plugs Control Nosebleeds Quickly, Effectively and Comfortably 2Health News:New HemCon/Seal-On Nasal Plugs Control Nosebleeds Quickly, Effectively and Comfortably 3Health News:Healing Depression The Mind-Body Way Aims to 'Depression-Proof' Your Life 2Health News:Stopping harmful oral bacteria in its path is goal for Case Western Reserve researcher 2Health News:Understanding the process of homosexual identity formation among Asian and Pacific Islander youth 2Health News:Understanding the process of homosexual identity formation among Asian and Pacific Islander youth 3
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... Building on over 20 years of ... platforms for the Life Sciences, the ... flexibility and possibilities for expansion according ... new easy-to-use software, Freedom EVOware, each ...
... (OSS) from Biomet Inc. offers the ... specifically for orthopaedic surgeons and oncologists ... their patients: significant bone loss, ligamentous ... arthroplasties, and multiple hip revision arthroplasties. ...
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
Medicine Products: